196 related articles for article (PubMed ID: 23041219)
21. In vitro and in vivo anti-tumor activities of a gemcitabine derivative carried by nanoparticles.
Sloat BR; Sandoval MA; Li D; Chung WG; Lansakara-P DS; Proteau PJ; Kiguchi K; DiGiovanni J; Cui Z
Int J Pharm; 2011 May; 409(1-2):278-88. PubMed ID: 21371545
[TBL] [Abstract][Full Text] [Related]
22. N-trimethyl chitosan coated nano-complexes enhance the oral bioavailability and chemotherapeutic effects of gemcitabine.
Chen G; Svirskis D; Lu W; Ying M; Li H; Liu M; Wen J
Carbohydr Polym; 2021 Dec; 273():118592. PubMed ID: 34560993
[TBL] [Abstract][Full Text] [Related]
23. EGFR-targeted gelatin nanoparticles for systemic administration of gemcitabine in an orthotopic pancreatic cancer model.
Singh A; Xu J; Mattheolabakis G; Amiji M
Nanomedicine; 2016 Apr; 12(3):589-600. PubMed ID: 26656632
[TBL] [Abstract][Full Text] [Related]
24. H-gemcitabine: a new gemcitabine prodrug for treating cancer.
Dasari M; Acharya AP; Kim D; Lee S; Lee S; Rhea J; Molinaro R; Murthy N
Bioconjug Chem; 2013 Jan; 24(1):4-8. PubMed ID: 23237198
[TBL] [Abstract][Full Text] [Related]
25. Paclitaxel and gemcitabine combinational drug-loaded mucoadhesive delivery system in the treatment of colon cancers.
Guo XY; Wang P; Du QG; Han S; Zhu SM; Lv YF; Liu GS; Hao ZM
Drug Res (Stuttg); 2015 Apr; 65(4):199-204. PubMed ID: 24941086
[TBL] [Abstract][Full Text] [Related]
26. PEGylated liposomal Gemcitabine: insights into a potential breast cancer therapeutic.
Papa AL; Sidiqui A; Balasubramanian SU; Sarangi S; Luchette M; Sengupta S; Harfouche R
Cell Oncol (Dordr); 2013 Dec; 36(6):449-57. PubMed ID: 24081907
[TBL] [Abstract][Full Text] [Related]
27. N-trimethyl chitosan nanoparticles and CSKSSDYQC peptide: N-trimethyl chitosan conjugates enhance the oral bioavailability of gemcitabine to treat breast cancer.
Chen G; Svirskis D; Lu W; Ying M; Huang Y; Wen J
J Control Release; 2018 May; 277():142-153. PubMed ID: 29548985
[TBL] [Abstract][Full Text] [Related]
28. Lessons Learned from Gemcitabine: Impact of Therapeutic Carrier Systems and Gemcitabine's Drug Conjugates on Cancer Therapy.
Dyawanapelly S; Kumar A; Chourasia MK
Crit Rev Ther Drug Carrier Syst; 2017; 34(1):63-96. PubMed ID: 28322141
[TBL] [Abstract][Full Text] [Related]
29. Codelivery of dual drugs from polymeric micelles for simultaneous targeting of both cancer cells and cancer stem cells.
Krishnamurthy S; Ng VW; Gao S; Tan MH; Hedrick JL; Yang YY
Nanomedicine (Lond); 2015; 10(18):2819-32. PubMed ID: 26377155
[TBL] [Abstract][Full Text] [Related]
30. Mixed micelles of lipoic acid-chitosan-poly(ethylene glycol) and distearoylphosphatidylethanolamine-poly(ethylene glycol) for tumor delivery.
Elsaid Z; Taylor KM; Puri S; Eberlein CA; Al-Jamal K; Bai J; Klippstein R; Wang JT; Forbes B; Chana J; Somavarapu S
Eur J Pharm Sci; 2017 Apr; 101():228-242. PubMed ID: 28163163
[TBL] [Abstract][Full Text] [Related]
31. Preparation and characterization of 5-fluorouracil-loaded PLLA-PEG/PEG nanoparticles by a novel supercritical CO2 technique.
Zhang C; Li G; Wang Y; Cui F; Zhang J; Huang Q
Int J Pharm; 2012 Oct; 436(1-2):272-81. PubMed ID: 22721846
[TBL] [Abstract][Full Text] [Related]
32. Polymeric Micelles of PEG-PLA Copolymer as a Carrier for Salinomycin Against Gemcitabine-Resistant Pancreatic Cancer.
Daman Z; Montazeri H; Azizi M; Rezaie F; Ostad SN; Amini M; Gilani K
Pharm Res; 2015 Nov; 32(11):3756-67. PubMed ID: 26228105
[TBL] [Abstract][Full Text] [Related]
33. Improving Plasma Stability and Bioavailability In Vivo of Gemcitabine Via Nanoparticles of mPEG-PLG-GEM Complexed with Calcium Phosphate.
Chu W; Tian P; Ding N; Cai Q; Li J; Zhuo X; Tang Z; Gou J; Yin T; Zhang Y; He H; Tang X
Pharm Res; 2018 Oct; 35(12):230. PubMed ID: 30327887
[TBL] [Abstract][Full Text] [Related]
34. Enhanced tumor delivery of gemcitabine via PEG-DSPE/TPGS mixed micelles.
Wang Y; Fan W; Dai X; Katragadda U; Mckinley D; Teng Q; Tan C
Mol Pharm; 2014 Apr; 11(4):1140-50. PubMed ID: 24579673
[TBL] [Abstract][Full Text] [Related]
35. Preparation, physicochemical characterization and cytotoxicity in vitro of gemcitabine-loaded PEG-PDLLA nanovesicles.
Jia L; Zheng JJ; Jiang SM; Huang KH
World J Gastroenterol; 2010 Feb; 16(8):1008-13. PubMed ID: 20180242
[TBL] [Abstract][Full Text] [Related]
36. Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acid-poly(ethylene glycol)-chitosan oligosaccharide lactate nanoparticles: for the potential targeted ovarian cancer gene therapy.
Li TS; Yawata T; Honke K
Eur J Pharm Sci; 2014 Feb; 52():48-61. PubMed ID: 24178005
[TBL] [Abstract][Full Text] [Related]
37. Gemcitabine-loaded chitosan microspheres. Characterization and biological in vitro evaluation.
Ventura CA; Cannavà C; Stancanelli R; Paolino D; Cosco D; La Mantia A; Pignatello R; Tommasini S
Biomed Microdevices; 2011 Oct; 13(5):799-807. PubMed ID: 21607718
[TBL] [Abstract][Full Text] [Related]
38. Development of Asialoglycoprotein Receptor-Targeted Nanoparticles for Selective Delivery of Gemcitabine to Hepatocellular Carcinoma.
Nair AB; Shah J; Al-Dhubiab BE; Patel SS; Morsy MA; Patel V; Chavda V; Jacob S; Sreeharsha N; Shinu P; Attimarad M; Venugopala KN
Molecules; 2019 Dec; 24(24):. PubMed ID: 31847085
[TBL] [Abstract][Full Text] [Related]
39. pH-Sensitive Nanodrug Carriers for Codelivery of ERK Inhibitor and Gemcitabine Enhance the Inhibition of Tumor Growth in Pancreatic Cancer.
Ray P; Dutta D; Haque I; Nair G; Mohammed J; Parmer M; Kale N; Orr M; Jain P; Banerjee S; Reindl KM; Mallik S; Kambhampati S; Banerjee SK; Quadir M
Mol Pharm; 2021 Jan; 18(1):87-100. PubMed ID: 33231464
[TBL] [Abstract][Full Text] [Related]
40. Gemcitabine-loaded Folic Acid Tagged Liposomes: Improved Pharmacokinetic and Biodistribution Profile.
Unnam S; Panduragaiah VM; Sidramappa MA; Muddana Eswara BR
Curr Drug Deliv; 2019; 16(2):111-122. PubMed ID: 30360740
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
